1 week ago
AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study
AstraZeneca (AZN) stock gained 1% after halting its Phase III lung cancer trial. Data monitoring committee found volrustomig combo unlikely to succeed.
The post AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study appeared first on Blockonomi.
Source: Blockonomi →Related News
- 11 hours ago
The Trade Desk, Inc. (TTD) Stock: New Zuma Platform Brings Smarter AI, Simpler M...
- 11 hours ago
Laser Photonics Corporation (LASE) Stock: SOCOM Engagement Puts Counter-Drone Sy...
- 14 hours ago
Amazon (AMZN) Stock: Expands Nvidia Partnership as AI Demand Grows
- 14 hours ago
Marvell Technology (MRVL) Q2 Earnings Preview: Should Investors Buy Before Thurs...
- 14 hours ago
Nvidia (NVDA), Salesforce (CRM), CrowdStrike (CRWD), and Okta (OKTA) Soar as AI...